Naloxegol oxalate is a Small Molecule owned by AstraZeneca, and is involved in 27 clinical trials, which were completed.
Naloxegol is a peripherally-acting mu opioid antagonist. It antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor. Opioids play an important role in chronic pain relief. They work by binding to mu-receptors in the central nervous system, but they also bind to mu-receptors in the gastrointestinal tract, which can result in patients suffering from OIC(opioid-induced constipation). Naloxegol acts on mu-receptors in the gastrointestinal tract elliciting antagonist activity, such as to provide relief from opioid-induced constipation.
The revenue for Naloxegol oxalate is expected to reach a total of $334m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Naloxegol oxalate NPV Report.
Naloxegol oxalate Overview
Naloxegol oxalate (Movantik, Moventig, PEG-Naloxol) is an anti-constipation agent. It is formulated as pegylated film coated tablets for oral route of administration. Naloxegol is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
Kyowa Kirin Overview
Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.
Quick View – Naloxegol oxalate
|Highest Development Stage|